OBJECTIVE: Treatment of renal cell carcinoma (RCC) with radical nephrectomy (RN) induces chronic kidney disease more frequently compared with nephron-sparing surgery (NSS), which may have an impact on overall survival. Thus, NSS is recommended for RCCs up to 7 cm (T1). The aim of this study was to determine the extent to which these recommendations are implemented in clinical practice. MATERIAL AND METHODS: Data were extracted from the Swedish National Kidney Cancer Register, a population-based register covering 98% of all RCCs in Sweden. In total, 3158 patients (1892 men, 1266 women) were primarily diagnosed with cT1N0M0 and treated surgically during 2005-2011. The administered treatments were evaluated between different hospitals as well as between the 21 independent healthcare counties. RESULTS: In all, 742 patients were treated with NSS, 2339 with RN and 77 with minimally invasive ablative treatments. For cT1a RCC, patients treated with NSS increased from 22% in 2005 to 53% in 2011, and for cT1b from 2% to 10%. Nephron-sparing treatments for cT1a RCC were performed in 62% in university hospitals, 34% in intermediate- and 11% in low-volume hospitals. There was significant (p < 0.001) variation (31-67%) between the university hospitals and also for patient care in the 21 different counties (16-78%). There was an increased relative survival after NSS for T1a patients compared with RN. The register design by itself indicates limitations using data gathered from all Swedish hospitals. CONCLUSIONS: NSS was underutilized in many hospitals and a patient's chance of being offered NSS varied according to their place of residence. Patients with cT1a RCC treated with NSS had a significantly better relative survival than those treated with RN.
OBJECTIVE: Treatment of renal cell carcinoma (RCC) with radical nephrectomy (RN) induces chronic kidney disease more frequently compared with nephron-sparing surgery (NSS), which may have an impact on overall survival. Thus, NSS is recommended for RCCs up to 7 cm (T1). The aim of this study was to determine the extent to which these recommendations are implemented in clinical practice. MATERIAL AND METHODS: Data were extracted from the Swedish National Kidney Cancer Register, a population-based register covering 98% of all RCCs in Sweden. In total, 3158 patients (1892 men, 1266 women) were primarily diagnosed with cT1N0M0 and treated surgically during 2005-2011. The administered treatments were evaluated between different hospitals as well as between the 21 independent healthcare counties. RESULTS: In all, 742 patients were treated with NSS, 2339 with RN and 77 with minimally invasive ablative treatments. For cT1a RCC, patients treated with NSS increased from 22% in 2005 to 53% in 2011, and for cT1b from 2% to 10%. Nephron-sparing treatments for cT1a RCC were performed in 62% in university hospitals, 34% in intermediate- and 11% in low-volume hospitals. There was significant (p < 0.001) variation (31-67%) between the university hospitals and also for patient care in the 21 different counties (16-78%). There was an increased relative survival after NSS for T1a patients compared with RN. The register design by itself indicates limitations using data gathered from all Swedish hospitals. CONCLUSIONS: NSS was underutilized in many hospitals and a patient's chance of being offered NSS varied according to their place of residence. Patients with cT1a RCC treated with NSS had a significantly better relative survival than those treated with RN.
Authors: Javier González; José Manuel Cózar; Antonio Gómez; Cristina Fernández-Pérez; Manuel Esteban Journal: Curr Urol Rep Date: 2015-02 Impact factor: 3.092
Authors: Hyung Keun Kim; Jong Hyun Pyun; Jae Yoon Kim; Seung Bin Kim; Seok Cho; Sung Gu Kang; Jeong Gu Lee; Je Jong Kim; Jun Cheon; Seok Ho Kang Journal: Korean J Urol Date: 2015-02-02
Authors: Katja K H Aben; Susanne Osanto; Christina A Hulsbergen-van de Kaa; Patricia M Soetekouw; Daphne Stemkens; Axel Bex Journal: World J Urol Date: 2016-05-13 Impact factor: 4.226
Authors: Milan Hora; Viktor Eret; Ivan Trávníček; Kristýna Procházková; Tomáš Pitra; Olga Dolejšová; Ondřej Hes; Fredrik Petersson Journal: Cent European J Urol Date: 2016-09-22
Authors: Andreas Thorstenson; Ulrika Harmenberg; Per Lindblad; Benny Holmström; Sven Lundstam; Börje Ljungberg Journal: Biomed Res Int Date: 2015-10-11 Impact factor: 3.411
Authors: Noor Nabi Junejo; Sultan Saud Alkhateeb; Majed Faisal Alrumayyan; Khalid Yusuf Alkhatib; Hassan Messfer Alzahrani; Mohammed Faihan Alotaibi; Khalid Ibrahim Alothman; Turki Omar Al-Hussain; Waleed Mohamed Altaweel Journal: Urol Ann Date: 2021-03-04